Filing Flows › China Pharma Holdings (CPHI) › Q3 2025
China Pharma Holdings (CPHI) Q3 2025 earnings results (third quarter 2025)
10-Q filed Nov 12, 2025
China Pharma Holdings (CPHI) reported revenue of $756K for the third quarter 2025 (Q3 2025), -31% from a year earlier and -26% from the quarter before. Operating margin was -83.1%, net loss $651K (86.2% of revenue).
China Pharma Holdings, Q3 2025: revenue $756K (-31% year over year), operating margin -83.1%, net loss $651K, operating cash flow −$237K. The chart follows the revenue to costs, profit and cash.
| Q3 2025 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $756K | -26% | -31% |
| Operating profit | −$628K | — | — |
| Net earnings | −$651K | — | — |
| Operating cash flow | −$237K | -181% | — |
What changed
Revenue was $756K in Q3 2025, down 31% year over year and down 26% from the previous quarter.
Operating costs exceeded revenue by $628K, an operating margin of -83.1%. Total costs fell 37% while revenue fell 31%. The fastest-growing cost line was General & admin (+23%). The quarter ended with a net loss of $651K, wider than the previous quarter's $528K loss.
Operating cash flow was −$237K. Non-cash charges added back $356K of depreciation and amortization. Working capital and other items added $58K. Capital expenditures of $1K exceeded it, leaving free cash flow of −$238K.
Questions
What was China Pharma Holdings' revenue in the third quarter 2025?
China Pharma Holdings (CPHI) reported revenue of $756K for the third quarter 2025 (Q3 2025), -31% from a year earlier and -26% from the quarter before.
Was China Pharma Holdings profitable in the third quarter 2025?
Operating loss was $628K (-83.1% of revenue) and net loss $651K.